Novel Biology

Two antibodies with novel mechanisms of actions

Focused on Suppressing Immune Cell Activation

Target two key pathogenic cells shown to be highly relevant in Inflammation & Immunology

Significant Commercial Opportunity

Potential in Multiple Inflammation & Immunology Indications: Atopic Dermatitis, Chronic Urticaria and Eosinophilic Gastrointestinal Disorders

Lirentelimab (AK002)

An investigational monoclonal antibody that potently depletes eosinophils and inhibits mast cells

AK006

An investigational monoclonal antibody that selectively and potently inhibits mast cells, including KIT mediated signaling